Domača stranDCTH • NASDAQ
add
Delcath Systems Inc
11,06 $
Po zaprtju:(0,54 %)−0,060
11,00 $
Konec trgovanja: 8. nov., 19:39:12 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
10,94 $
Dnevni razpon
10,86 $ - 12,88 $
Letni razpon
2,25 $ - 12,88 $
Tržna kapitalizacija
309,69 mio. USD
Povprečni obseg
321,80 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 7,77 mio. | 1.468,89 % |
Stroški poslovanja | 10,16 mio. | 21,78 % |
Čisti dohodek | −13,74 mio. | −90,79 % |
Čista dobičkovnost prihodkov | −176,94 | 87,84 % |
Earnings per share | −0,48 | 17,24 % |
EBITDA | −3,88 mio. | 51,32 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 19,91 mio. | 36,91 % |
Skupna sredstva | 33,91 mio. | 61,11 % |
Skupne obveznosti | 13,91 mio. | −20,56 % |
Celoten lastniški kapital | 20,00 mio. | — |
Shares outstanding | 28,00 mio. | — |
Razmerje P/B | 72,93 | — |
Donosnost sredstev | −27,94 % | — |
Donosnost kapitala | −35,67 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −13,74 mio. | −90,79 % |
Denar iz dejavnosti | −4,45 mio. | 53,87 % |
Denar iz naložb | 10,28 mio. | 25.810,00 % |
Denar iz financiranja | −2,85 mio. | −40.871,43 % |
Neto sprememba denarnih sredstev | 2,97 mio. | 130,70 % |
Prost denarni tok | −2,46 mio. | 62,43 % |
Vizitka
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Generalni direktor
Datum ustanovitve
1988
Sedež organizacije
Spletno mesto
Zaposleni
76
